These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27891526)

  • 1. Comparative Effectiveness Research Using Observational Data: Active Comparators to Emulate Target Trials with Inactive Comparators.
    Huitfeldt A; Hernan MA; Kalager M; Robins JM
    EGEMS (Wash DC); 2016; 4(1):1234. PubMed ID: 27891526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance and implications of comparator selection in pharmacoepidemiologic research.
    D'Arcy M; Stürmer T; Lund JL
    Curr Epidemiol Rep; 2018 Sep; 5(3):272-283. PubMed ID: 30666285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness clinical trials in psychiatry: superiority, noninferiority, and the role of active comparators.
    Leon AC
    J Clin Psychiatry; 2011 Oct; 72(10):1344-9. PubMed ID: 21367350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparator choice in cariology trials limits conclusions on the comparative effectiveness of caries interventions.
    Schwendicke F; Innes N; Levey C; Lamont T; Göstemeyer G
    J Clin Epidemiol; 2017 Sep; 89():209-217. PubMed ID: 28652063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
    Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report.
    Berger ML; Dreyer N; Anderson F; Towse A; Sedrakyan A; Normand SL
    Value Health; 2012; 15(2):217-30. PubMed ID: 22433752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some methodological points to consider when performing systematic reviews in comparative effectiveness research.
    Berlin JA; Cepeda MS
    Clin Trials; 2012 Feb; 9(1):27-34. PubMed ID: 22049086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated generation of comparator patients in the electronic medical record.
    Rigdon J; Ostasiewski B; Woelfel K; Wiseman KD; Hetherington T; Downs S; Kowalkowski M
    Learn Health Syst; 2024 Jan; 8(1):e10362. PubMed ID: 38249842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of Comparator Group in Observational Drug Safety Studies: Alternatives to the Active Comparator New User Design.
    Wintzell V; Svanström H; Pasternak B
    Epidemiology; 2022 Sep; 33(5):707-714. PubMed ID: 35944152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data.
    Gray CM; Grimson F; Layton D; Pocock S; Kim J
    Drug Saf; 2020 Jul; 43(7):623-633. PubMed ID: 32440847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
    Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
    Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available.
    Hernán MA; Robins JM
    Am J Epidemiol; 2016 Apr; 183(8):758-64. PubMed ID: 26994063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Core concepts in pharmacoepidemiology: Confounding by indication and the role of active comparators.
    Sendor R; Stürmer T
    Pharmacoepidemiol Drug Saf; 2022 Mar; 31(3):261-269. PubMed ID: 35019190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethical pitfalls in neonatal comparative effectiveness trials.
    Modi N
    Neonatology; 2014; 105(4):350-1. PubMed ID: 24931328
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.